Mara Aspinall co-founded the Biomedical Diagnostics program at Arizona State University’s College of Health Solutions, which is the first program dedicated entirely to diagnostics as an independent discipline. She is Managing Partner of BlueStone Venture Partners and CEO of the Health Catalysts Group, a research and consulting firm for new healthcare companies. Aspinall is the former President and CEO of Ventana Medical Systems / Roche Tissue Diagnostics. Previously, she was President of Genzyme Genetics, the leading genetic testing company. She currently sits on the Board of Abcam, Allscripts, Castle Biosciences, Orasure, and BlueCross BlueShield of Arizona. Aspinall has spearheaded initiatives to educate payers and policymakers on genomics and personalized medicine. She served as an active member of the Health and Human Services Secretary’s Advisory Council on Genetics, Health & Society (SACGHS) in both the Bush and Obama administrations. Aspinall was also a Trustee of the Dana Farber Cancer Institute for 11 years, where she chaired the Trustee Science Committee.
Mara is a co-author of "Sensitive and Specific, The Testing Newsletter.” She currently serves as an advisor to the Rockefeller Foundation on COVID-19.
Interview with Mara (published November 2022) https://mendelspod.com/podcasts/what-state-covid-mara-aspinall-rockefell...
